Seeking Alpha

The number of drug authorizations for the world's top 12 pharmaceuticals companies increased to...

The number of drug authorizations for the world's top 12 pharmaceuticals companies increased to 41 over the past year from 32 in the previous year, but the expected revenues from these treatments fell around 30% to $211B. The trend highlights how productivity is declining in the R&D labs of Big Pharma as it struggles to offset the latest patent cliffs.
Comments (1)
  • dsr70
    , contributor
    Comments (1407) | Send Message
     
    The lead time from nascent drug research to approval is what, 10 years? The mini-boom in drug approval we've seen the past 2-3 years is the product of the early 2000's optimism of the biopharma industry. Going forward, with Obamacare and eventual single payer, the US market as the driver for research is coming to an end.

     

    Unless researchers are amply rewarded, and can keep those rewards, research won't take place. Pretty simple.
    4 Dec 2012, 07:16 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|